Reuters Health Information (2004-03-02): Roche says Pegasys can be tailored to hepatitis C genotype
Drug & Device Development
Roche says Pegasys can be tailored to hepatitis C genotype
Last Updated: 2004-03-02 16:11:51 -0400 (Reuters Health)
LONDON (Reuters) - Roche said on Tuesday a new clinical study showed its Pegasys hepatitis C drug can be tailored to suit the viral genotype.
Patients with easier-to-treat genotypes 2 and 3 can reduce the length of treatment by a half -- from one year to six months -- according to findings published in the Annals of Internal Medicine. They can also take a lower dose of ribavirin, which is given in combination with Pegasys, and still achieve a sustained virological response of 84%.